Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. - Wikidata - wikimedia - TriplyDB

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

http://www.wikidata.org/entity/Q41917701

about

Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity Evidence for early disease-modifying drugs in rheumatoid arthritis Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications Rheumatoid arthritis treatment: the earlier the better to prevent joint damage Gene expression analysis in RA: towards personalized medicine Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs Improving healthcare consumer effectiveness: an Animated, Self-serve, Web-based Research Tool (ANSWER) for people with early rheumatoid arthritis.Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis.Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?Impact of early diagnosis on functional disability in rheumatoid arthritis.Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases.Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis.Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis Clinical utility of the anti-CCP assay in patients with rheumatic diseases.Rheumatoid arthritis in 2003: where are we now with treatment?Infliximab in active early rheumatoid arthritis.Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.Heterogeneity of synovial molecular patterns in patients with arthritis.The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia.Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Radiological damage in patients with rheumatoid arthritis on sustained remission.Epidemiology and burden of illness of rheumatoid arthritis.Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.

P2860

Q24630655-D76935E3-29C7-4A39-9B1D-3132E8781A74 Q24793240-A5D0774E-7970-4F91-AC1F-F6553918D03D Q24816803-A825BA0F-9A4F-4AA2-8C8D-38B815C1D44D Q24817058-7E5E84DE-ADBB-4958-ACFF-18F64192ACF2 Q26738960-3F5A6C0A-8300-43EC-A1F6-404CC0770ADB Q26777903-B4FAEFEC-F778-40DB-B821-43CEAAC24F71 Q26825706-6BDAB64E-C465-4B1B-8CA1-A4454AD5C7CF Q33341162-17C03B0C-ADF5-462F-979F-ADAD50D350F7 Q33495384-A9E273AF-C2BD-4408-B633-9C543F2F7028 Q33540305-811918EB-D0A3-4254-8F8E-68622758EC14 Q33577429-08DD5FBD-16BA-4B73-A670-F963D6AFFB06 Q33669345-B48E187E-E9FC-4FA0-876A-578B6AAD65D8 Q33765844-CEED1A75-15E5-4BAE-8390-DE9EC6E48922 Q33840415-4C043B0F-5EE8-4197-B430-72C3CE120A36 Q33907199-05159B34-6519-409E-9A55-4D2F7138747C Q34237586-735245C8-32E0-400C-979D-75FC14767264 Q34486243-BC519080-3EAC-4DD4-9E23-13288ABEA294 Q34551260-7370160A-D6B3-480A-9180-12C667F9594E Q34559803-FDD8537C-EDFA-4BE4-8FC8-5AE91C896D65 Q34626240-2BAB5061-4336-464B-BB01-D49456ACCF84 Q35012150-B8B549A3-6791-4620-A621-11F7B82198F3 Q35085103-FEF0B41F-991D-4B6C-91D9-2D7D590CB89D Q35103421-F5D58361-E3FF-42DF-8549-D1328FC7DBC8 Q35135754-63D40784-F2B3-417A-A18A-5AFCA4952D79 Q35177819-D9F78DD3-7FD3-462B-BA58-91F4B918C307 Q35553110-D372676C-A0BB-4E3F-B67B-B3BC2A9B64C1 Q35553548-8EEBA201-EDEC-42BA-AED3-2B36ED48BE7B Q35553834-A2DD7C25-A794-4882-BE8B-25C161128070 Q35554180-823A6219-A927-483D-A22B-ACD98B0136BF Q35554508-376BF84B-EBAF-4F9E-AF5B-D43F5621FB06 Q35554643-38E7D86F-B2FE-48EA-BBA1-CCB9DC2557CF Q35557682-CBBFB205-9AA7-454B-990E-0D8EFD91BE92 Q35627227-C8D8A2D9-DB9C-47BA-B29E-12CFF37E3793 Q35636544-544DBD8B-B1D7-4EBE-AD69-A72CB3CADCD1 Q35636558-880B7921-BF0B-4D74-842F-B2061F8AF097 Q35637543-14B6671F-36BE-461B-AF35-4D3474875A36 Q35638360-9CD8903F-2105-43F9-87DC-78506391C77F Q35759974-FE4881DC-DF49-48C4-8613-C35199924598 Q35780338-B454FC8D-ED1D-42BD-B498-CC0BBAC3ECD5 Q35870808-A435B77A-CCE6-466D-9882-958E06D18259

P2860

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

http://www.wikidata.org/entity/Q41917701

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Delay to institution of therap ...... in early rheumatoid arthritis.

@en

type

label

Delay to institution of therap ...... in early rheumatoid arthritis.

@en

prefLabel

Delay to institution of therap ...... in early rheumatoid arthritis.

@en

P1433

Q41917701-2F37AAE1-BE1C-4AE8-BA8C-C0018EF4E891

P1476

Q41917701-69813072-7590-4055-8165-60798AEB64A1

P2093

Q41917701-074384C9-3E11-464E-B5AD-0ECE286E6F6F

Q41917701-15094E66-9FC9-4870-83AB-C65D4970A045

Q41917701-21DFE758-92D5-4C1D-B3EB-C92455D4687C

Q41917701-28997B14-4FA2-459D-B5B7-2AB38FDDC320

Q41917701-445BA9FB-AFDB-47EE-8E74-3F6999791D33

Q41917701-719A50B0-C926-419B-BDF5-4C5263388AB8

Q41917701-96E7E54E-2688-4E17-97C7-75A842527C57

Q41917701-9A603899-6144-41BF-9BA3-4A4F6914DB9B

Q41917701-B9D7931D-47EA-4016-A274-2BB832B44403

Q41917701-C2C5A54D-BC10-4712-AD7C-39137A96B934

P2860

Q41917701-3E4077D4-87E9-41EE-88EB-3775D8A7AABC

Q41917701-45464C12-C242-4B34-AF77-F9EA74B3C9B0

Q41917701-61A320E2-19A1-4DB7-9C25-C8E38FA30842

Q41917701-7A4DE98F-FCCD-4047-9BB7-ECF0B386CA6F

Q41917701-8B978862-A463-4F80-8CA3-D1037909076B

Q41917701-B272A111-B4DF-4BA5-A880-A0E556FF6AD4

Q41917701-E5924DDD-879C-45B0-A7E1-174E0E9C27F9

Q41917701-E8873AE5-F8DB-4D34-816D-6D5F0DC3E51D

Q41917701-F613129E-64B3-48DF-9427-0FAC82BF5427

Q41917701-F69762BA-3C88-46F2-9F17-A5B3C89355F6

P304

Q41917701-9F09E821-B03C-48B6-A5C1-C8B7A3E8623A

P31

Q41917701-BA82AEFA-F8DC-4CE1-89B3-00C6C1F50DDC

P356

Q41917701-DE16F95F-EA15-4BF7-BE3C-15A0564FAB91

P433

Q41917701-7022F93E-A4B6-4C98-8BF6-0655A42C8EAE

P478

Q41917701-161A9743-4429-4291-B746-C888298E5ADA

P50

Q41917701-7FF24DF2-4884-4FD5-B1E0-46CF139777C7

P577

Q41917701-A17E796F-CD4E-4A2D-8808-94C9A802A974

P5875

Q41917701-FFA66902-44CE-4827-9969-9917F60AA9AE

P698

Q41917701-3028CE8D-D8EC-4F6D-81A7-61B1A4EE86EA

P356

P1433

Arthritis and Rheumatism

P1476

Delay to institution of therap ...... in early rheumatoid arthritis

@en

P2093

FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy

http://www.w3.org/2001/XMLSchema#string

Hannu Kautiainen

http://www.w3.org/2001/XMLSchema#string

Jorma Ilonen

http://www.w3.org/2001/XMLSchema#string

Juhani Koski

http://www.w3.org/2001/XMLSchema#string

Leena Laasonen

http://www.w3.org/2001/XMLSchema#string

Marianne Gripenberg-Gahmberg

http://www.w3.org/2001/XMLSchema#string

Marjatta Leirisalo-Repo

http://www.w3.org/2001/XMLSchema#string

Markku Korpela

http://www.w3.org/2001/XMLSchema#string

Martti Nissilä

http://www.w3.org/2001/XMLSchema#string

Oili Kaipiainen-Seppänen

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Early rheumatoid arthritis: time to aim for remission?

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.

The lag time between onset of symptoms and diagnosis of rheumatoid arthritis.

Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.

Rational use of disease-modifying antirheumatic drugs.

Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis.

Measurement of patient outcome in arthritis

P304

894-898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.10135

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Timo Möttönen

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11413116

http://www.w3.org/2001/XMLSchema#string

P698

11953964

http://www.w3.org/2001/XMLSchema#string